Why ProMIS Neurosciences, Inc.’s (PMN) Stock Is Down 44.95%
As of Friday, October 30, ProMIS Neurosciences, Inc.’s PMN share price has dipped by 44.95%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Rosalio Madrigal
Michael Rose
Cynthia McLaughlin
| Share Statistics | PMN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $28.4 | $203.5 | 14% |
|
| Shares Out (Mil) | 9.1 | 55.2 | 20% |
|
| Institutional Ownership | 76.9% | 93.3% | 46% |
|
| Float (Mil) | 3.9 | 40.4 | 10% |
|
| Beta | -0.21 | 1.05 | 3% |
|
| Avg Daily Volume (000s) | 141 | 569 | 40% |
|
| Price Change (52-week) |
(69.6%) | 38.8% | 14% |
|
| Growth | PMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (55.3%) | (10.7%) | 6% |
|
| EPS (5yr) | 0.6% | 15.4% | 32 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (4.2%) | (15.7%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | na | 2 | |
| Current EPS | ($1.189) | na | ($3.985) | |
| Month Ago EPS | ($1.365) | na | ($4.511) | |
| # Rev Up | 1 | na | 0 | |
| # Rev Down | 0 | na | 0 | |
| Three Months Ago EPS | ($1.365) | na | ($4.511) | |
| Year/Year Chg | 33.1% | na | na | |
| Financials | PMN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($39) | ($44) | 18% |
|
| EPS (TTM) | ($5.647) | ($1.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($35) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($13) | $142 | 2% |
|
| Valuation | PMN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.68 | 1.96 | 18% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | PMN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (113.1%) | (47.0%) | 4% |
|
| ROE | (152.3%) | (51.8%) | 6% |
|
| Liabilities to Assets | 11.4% | 29.6% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
ProMIS Neurosciences, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors